Press "Enter" to skip to content

New patent for Glaxosmithkline drug TRELEGY ELLIPTA

2
Copyright © DrugPatentWatch. Originally published at New patent for Glaxosmithkline drug TRELEGY ELLIPTA

Annual Drug Patent Expirations for TRELEGY+ELLIPTA
Annual Drug Patent Expirations for TRELEGY+ELLIPTA

Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are nineteen patents protecting this drug.

TRELEGY ELLIPTA drug price trends.

Drug patent litigation for TRELEGY ELLIPTA.

This drug has four hundred and fifty-four patent family members in fifty-two countries.

The generic ingredient in TRELEGY ELLIPTA is fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. One supplier is listed for this compound. Additional details are available on the fluticasone furoate; umeclidinium bromide; vilanterol trifenatate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Glaxosmithkline drug TRELEGY ELLIPTA
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

Do NOT follow this link or you will be banned from the site!